NCT Number: NCT02865863
A Study to Evaluate the Effect of a Study Product on Quality of Life and Mood
A phase II randomized, placebo controlled study evaluating the efficacy of Eurycomalongifoliawater extract (Physta®)+Multivitamin on quality of life and mood on 86 healthy adults over a 24 week supplementation period.
Looking for future studies?
Notify MeKey information
Conditions
Age range
25 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy subjects ≥ 25 and ≤ 65 years of age.
- Body mass index (BMI) ≥ 18 and ≤30 kg/m2.
- Subjects must be employed in a job/position that has some degree of responsibility such that they experience a mid-level of stress at work.
- Subjects with a score of ≤ 18 in the Tension subscale and a score of ≤ 14 in the Fatigue subscale of the POMS Questionnaire.
- Judged by the Investigator to be in general good health on the basis of medical history.
- Females of child-bearing potential must agree to use appropriate birth control methods during the study.
- Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator
- Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator
Exclusion criteria
- Subjects with any history of immune system disorder or auto-immune disorder including but not limited to the following:
*AIDS, HIV, Ankylosing Spondylitis, Chronic Fatigue Syndrome, CREST syndrome, Crohn's disease, Dermatomyositis, Fibromyalgia, Grave's disease, Hashimoto's Thyroiditis, Lupus, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, PolyarteritisNodosa, Primary Biliary Cirrhosis, Psoriasis, Reynaud's Syndrome, Rhematoid Arthritis, Sarcoidosis, Scleroderma, Sjogren's Syndrome, Temporal Arthritis, Ulcerative Colitis, and Vitiligo
- Use of any immunosuppressive drugs in the last 12 months (including steroids or biologics)
- Any significant GI condition that would severely interfere with the evaluation of the study product including but not limited to inflammatory bowel disease (Ulcerative Colitis or Chron's), history of frequent diarrhea, history of surgery for weight loss (including gastric bypass or lapband), history of perforation of the stomach or intestines, gastroparesis, clinically important lactose intolerance
- Any active infection, or infection in the last month requiring antibiotics, antiviral medication, or hospitalization History or presence of cancer in the prior two years, except for non-melanoma skin cancer.
- Subjects with a history of seizure
- Recent history of (within 12 months) or strong potential for alcohol or substance abuse.
- Participation in a clinical study with exposure to any non-registered drug product within 30 days prior.
- Subject who are using herbal products containing androgenic/anxiolytic activity within 30 days (one month washout is allowed)
- Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk. Including subjects who are Bed or wheelchair-bound
- Untreated or unstable Hypothyroidism
- Subjects with active eating disorder including anorexia nervosa, bulimia, and/or obsessive compulsive eating disorders
- Central Neurological disorders including but not limited to Spinal cord injuries, multiple sclerosis, Parkinson's disease
- Pregnant, lactating, planning to become pregnant or unwilling to use adequate contraception during the duration of the study.
Treatment and study plan
Placebo
Dietary SupplementMultivitamin
Dietary SupplementPrimary outcomes
-
The change in quality of life after 24 weeks of supplementation with study product, measured using the SF-12 Quality of Life Questionnaire
Time frame: 24 Week
-
The change in mood after 24 weeks of supplementation with study product, measured using the POMS Questionnaire
Time frame: 24 week
Secondary outcomes
-
The change in stress after 24 weeks of supplementation with study product, measured using the Multi-Modal Stress Questionnaire
Time frame: 24 weeks
-
The change in fasting AM Cortisol levels after 24 weeks of supplementation with study product.
Time frame: 24 weeks
Other outcomes
-
The change in CBC levels after 24 weeks of supplementation with study product
Time frame: 24 weeks
-
The change in CMP results after 24 weeks of supplementation with study product
Time frame: 24 weeks
-
The change in urinalysis results after 24 weeks of supplementation with study product
Time frame: 24 weeks
-
The number of adverse events reported after 24 weeks of supplementation with study product
Time frame: 24 weeks
-
The change in lipid panel results after 24 weeks of supplementation with study product
Time frame: 24 weeks
-
The change in total testosterone results after 24 weeks of supplementation with study product
Time frame: 24 weeks
-
The change in free testosterone results after 24 weeks of supplementation with study product
Time frame: 24 weeks
Sponsors and collaborators
Lead sponsor
KGK Science Inc.
Industry
Collaborators
- Biotropics Malaysia Berhad
Registry information
Official study title
Safety and Efficacy Profile of the Eurycomalongifoliawaterextract (Physta®)+Multivitamin Study Product
Important dates
- Study start
- 2014
- Primary completion
- 2015
- First posted
- Aug 15, 2016
- Registry last updated
- Feb 27, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
SimpleC Wellness Platform With Social Robot Interaction
NCT05296239
Aging, Behavior
Athens, Georgia, United States
View Trial DetailsSimpleC Wellness Platform With Social Robot Interaction (Long-term)
NCT05599503
Aging Well, Behavior
Athens, Georgia, United States
View Trial DetailsMusic Therapy for Persons With Dementia
NCT03643003
Alzheimer Disease, Brain Diseases
Iowa City, Iowa, United States
View Trial DetailsEffects of a Proactive Social Robot for Older Adults in Reducing Loneliness and Social Isolation
NCT03972787
Loneliness, Mood
San Francisco, California, United States
View Trial Details